Medical and Pharmaceutical Combining mammograms with lung cancer screening can boost female uptake A recent study from Stanford Medicine made this conclusion Rowan DunneJune 4, 2025
Medical and Pharmaceutical Australia’s first national lung cancer screening program begins in July The aim of the game is to save 12,000 lives by 2035 Rowan DunneJune 3, 2025
Medical and Pharmaceutical DNA blood biopsy to identify personalized treatments for lung cancer patients Thousands in the UK will soon benefit from the state-of-the-art test developed by Guardant Health Rowan DunneMay 30, 2025
Medical and Pharmaceutical Against the rise of early onset cancer: a Mugglehead roundup Cancer treatment markets are set to expand rapidly over the next decade Joseph MortonMay 29, 2025
Medical and Pharmaceutical Lucid Diagnostics joins Russell 2000 and 3000 indexes Investment managers and institutional investors widely use the Russell indexes for both index funds and active investment benchmarks Joseph MortonMay 27, 2025
Medical and Pharmaceutical Phase Scientific International advances urine biopsy tech with $34M fundraising round The company has gained strong market traction by launching over 30 diagnostic products across multiple health categories Joseph MortonMay 26, 2025
Medical and Pharmaceutical Prenetics Global shares spike on significant revenue developments The company projects 2025 revenue to range between USD$73 million and USD$85 million Joseph MortonMay 22, 2025
Medical and Pharmaceutical Researcher wants to know if supplement can lessen risk of radon-linked lung cancer Him and his team have C$1.7M at their disposal for the next few years to find out Rowan DunneMay 21, 2025
Medical and Pharmaceutical Johnson & Johnson subsidiary sued for USD$147M for breaching antitrust rules in California The lawsuit exposes and brings closer scrutiny to “potentially anticompetitive” tactics by original equipment manufacturers Joseph MortonMay 21, 2025
Medical and Pharmaceutical Regeneron Pharmaceuticals gets access to biometric data for 15 million people When 23andMe collapsed financially, its genetic data quickly attracted attention as a lucrative asset Joseph MortonMay 20, 2025